Gene-Driven Adjuvant Therapy for NSCLC Leads to Big Improvement in DFS

(MedPage Today) — CHICAGO — Biomarker-driven adjuvant therapy for intermediate/high-risk non-small cell lung cancer (NSCLC) led to significantly longer disease-free survival (DFS) as compared with observation, a randomized trial showed.
DFS…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115810

Author :

Publish date : 2025-05-31 12:00:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31

Gene-Driven Adjuvant Therapy for NSCLC Leads to Big Improvement in DFS

The Covid Inquiry Podcast: ‘I wasn’t the decision maker’

Sacituzumab or Chemo in First-Line TNBC: Which Is Better?

Related Posts

CGM Receiver Recall; Interchangeable Novolog Biosimilar OK’d; Barbie With Diabetes

Is it Time to Modernize the Residency Match Process?

Cancer Drugs for Alzheimer’s? Gene Therapy Distribution Halted; Reframing APOE4

HHS Targets Transplant System Amid Reports of Donors Showing ‘Signs of Life’

NICE Backs Betula Verrucosa for Birch Pollen Allergies

Tiny elusive gecko rediscovered on one of the Galapagos islands

CGM Receiver Recall; Interchangeable Novolog Biosimilar OK’d; Barbie With Diabetes

Is it Time to Modernize the Residency Match Process?

Cancer Drugs for Alzheimer’s? Gene Therapy Distribution Halted; Reframing APOE4

HHS Targets Transplant System Amid Reports of Donors Showing ‘Signs of Life’

NICE Backs Betula Verrucosa for Birch Pollen Allergies

Tiny elusive gecko rediscovered on one of the Galapagos islands

Heart Attack Mix-Ups; New Transplant Risk Score; Discounted Direct-to-Patient DOAC

The Dangers of Crowdsourced ‘Cures’ for Long COVID

Categories

Archives